<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Panteleev PV</submitter><funding>Russian Science Foundation</funding><pagination>438</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10145973</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>13(4)</volume><pubmed_abstract>Proline-rich antimicrobial peptides (PrAMPs) having a potent antimicrobial activity and a modest toxicity toward mammalian cells attract much attention as new templates for the development of antibiotic drugs. However, a comprehensive understanding of mechanisms of bacterial resistance development to PrAMPs is necessary before their clinical application. In this study, development of the resistance to the proline-rich bovine cathelicidin Bac7&lt;sub>1-22&lt;/sub> derivative was characterized in the multidrug-resistant &lt;i>Escherichia coli&lt;/i> clinical isolate causing the urinary tract infection. Three Bac7&lt;sub>1-22&lt;/sub>-resistant strains with ≥16-fold increase in minimal inhibitory concentrations (MICs) were selected by serially passaging after four-week experimental evolution. It was shown that</pubmed_abstract><journal>Membranes</journal><pubmed_title>Genomic Insights into Bacterial Resistance to Proline-Rich Antimicrobial Peptide Bac7.</pubmed_title><pmcid>PMC10145973</pmcid><funding_grant_id>21-74-00100</funding_grant_id><pubmed_authors>Ovchinnikova TV</pubmed_authors><pubmed_authors>Kruglikov RN</pubmed_authors><pubmed_authors>Bolosov IA</pubmed_authors><pubmed_authors>Safronova VN</pubmed_authors><pubmed_authors>Panteleev PV</pubmed_authors></additional><is_claimable>false</is_claimable><name>Genomic Insights into Bacterial Resistance to Proline-Rich Antimicrobial Peptide Bac7.</name><description>Proline-rich antimicrobial peptides (PrAMPs) having a potent antimicrobial activity and a modest toxicity toward mammalian cells attract much attention as new templates for the development of antibiotic drugs. However, a comprehensive understanding of mechanisms of bacterial resistance development to PrAMPs is necessary before their clinical application. In this study, development of the resistance to the proline-rich bovine cathelicidin Bac7&lt;sub>1-22&lt;/sub> derivative was characterized in the multidrug-resistant &lt;i>Escherichia coli&lt;/i> clinical isolate causing the urinary tract infection. Three Bac7&lt;sub>1-22&lt;/sub>-resistant strains with ≥16-fold increase in minimal inhibitory concentrations (MICs) were selected by serially passaging after four-week experimental evolution. It was shown that</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Apr</publication><modification>2025-04-21T17:26:04.266Z</modification><creation>2025-04-05T16:40:46.737Z</creation></dates><accession>S-EPMC10145973</accession><cross_references><pubmed>37103865</pubmed><doi>10.3390/membranes13040438</doi></cross_references></HashMap>